Study Report
                    
                            
                           Reference
                        
 
                    
                    
                        
                            | Citation | Sawada, 2002  PubMed | 
                        
                            | Full Info | Sawada, K., Young, C.E., Barr, A.M., Longworth, K., Takahashi, S., Arango, V., Mann, J.J., Dwork, A.J., Falkai, P., Phillips, A.G. et al. (2002) Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness. Mol Psychiatry, 7, 484-492. | 
                    
                     
                        
                    
                            
                           Study
                        
 
                    
                    
                        
                            | Hypothesis or Background | Recent imaging and postmortem studies suggest that impaired connectivity is involved in the pathophysiology of schizophrenia and major affective disorders | 
                        | Sample Information | schizophrenia (n = 13; six suicide, seven nonsuicide), major depression (n= 11, all suicide) and controls (n = 11) | 
|---|
                        
                            | Method Detail | We investigated the presynaptic proteins complexin (Cx) I and Cx II in postmortem prefrontal cortex in schizophrenia (n = 13; six suicide, seven nonsuicide), major depression (n= 11, all suicide) and controls (n = 11) with an enzyme-linked immunoadsorbent assay (ELISA). | 
                        
                            | Method Keywords | Enzyme-linked immunosorbent assay (ELISA) | 
                        
                            | Result | Overall analysis indicated a significant difference between groups (F = 3.93, P = 0.007). Cx I (enriched in inhibitory terminals) was decreased 33% in schizophrenia (26% in schizophrenia/nonsuicide, 42% in schizophrenia/suicide) and 27% in major depression. Cx II (enriched in excitatory terminals) was not significantly different. Analysis of the ratio of Cx II/Cx I was carried out as an indication of the balance of excitatory to inhibitory terminals. A significant difference between groups (ANOVA, F = 6.42, P = 0.005) was observed. The mean value of Cx II/Cx I was significantly increased by 34% in schizophrenia (26% in schizophrenia/nonsuicide and 43% in schizophrenia/suicide) and by 32% in depression compared with control (Student-Newman-Keuls test, P = 0.05). Immunoreactivities of the two complexins were highly correlated in all groups. However, compared with controls and depression, samples from cases with schizophrenia appeared to have relatively less Cx I for similar amounts of Cx II. Immunocytochemical studies of rat frontal cortex after 3 weeks treatment with chlorpromazine, trifluoperazine or haloperidol revealed no differences in complexins, synaptophysin, SNAP-25, syntaxin or VAMP in comparison with animals treated with vehicle. | 
                        
                        
                            | Conclusions | Alterations of complexins may contribute to the molecular substrate for abnormalities of neural connectivity in severe mental disorders. | 
                        
                        
                    
                     
                        
                    
                            
                           Relationships reported by 
Sawada, 2002
                         
                    
                    
                        
                            | Component A Approved Name (Name in Paper) | Component A Type | Component B Approved Name (Name in Paper) | Component B Type | Statistical Result | Relationship Description | Result Category (Positive/Negative)) | 
                        
                        
                            
                            
                                
                                
                                    
                                
                            
                                | MDD | syndrome | Complexin-1 (proteins complexin (Cx) I) | protein |  | Cx I (enriched in inhibitory terminals) was decreased 33% in schizophrenia (26% in schizophrenia/nonsuicide, 42% in schizophrenia/suicide) and 27% in major depression. | Positive |